Peptimmune: Experienced Leadership

About Our Company

Our Headquarters
Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP™ Technology to design peptides and peptide mixtures.

Learn more

Meet Our Team

Ed Mascioli, MD

Ed Mascioli, MD

Vice President, Clinical Affairs
Prior to Peptimmune, he was at MPM Capital, a leading healthcare venture capital firm. While at MPM, he served on the boards of Arriva Pharmaceuticals, CGI Pharmaceuticals, Elixir Pharmaceuticals, Mindset, Oxagen, Peptimmune…

Learn more

Latest News

Peptimmune to Collaborate on Dengue Virus Vaccine and Point-of-Care Diagnostic with two DOD biomedical research facilities

Cambridge, Mass. Peptimmune, Inc. announced today that it has formed a research and development collaboration…

Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients

CAMBRIDGE, Mass. - Peptimmune announced today the completion of a clinical trial to evaluate the safety,…

View all

Upcoming Events

There are no events scheduled at the moment, please check back soon.

Pipeline

PI-2301 is a second-generation peptide copolymer that has superior efficacy and convenience profile compared to Copaxone® for the treatment of Multiple Sclerosis.

Learn more

Platform Technology

DEEP™ Technology - Directed Expansion of an Epitope through Permutating native or novel peptide sequences

Antibodies | Novel Therapeutics | Vaccines

Learn more

Patient Information

Multiple Sclerosis Trial Notice - Peptimmune is now Enrolling Patients in France with Secondary Progressive Multiple Sclerosis (SPMS)

Learn more